구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Carmustine |
Overview Company | INSYS Therapeutics Inc |
Overview Modality | ANTIBODY |
Overview Target | Human Immunodeficiency Virus 1 Positive |
Overview Indication | Mantle Cell Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | targeted nanodelivery system, denoted BCNU-FeSeH@EV LF , which integrates magnetic guidance, chemotactic homing, and receptor |
MoA Biomarker | biomarker for hepatocellular carcinoma,lung adenocarcinoma,and papillary renal cell carcinoma |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Rat |
Toxicology Animal (cat.) | Rat |
Toxicology Major finding | Toxicity and efficacy of four carmustine-substituted conditioning regimens followed by autologous stem cell transplantation in lymphoma: a real-world comparative study.. High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) remains a key consolidation strategy for patients with relapsed/refractory (R/R) lymphoma. The BEAM regimen (carmustine, etoposide, cytarabine, melphal… |
Toxicology CRS | Reported |
Clinical Safety signal | Toxicity and efficacy of four carmustine-substituted conditioning regimens followed by autologous stem cell transplantation in lymphoma: a real-world comparative study.. High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) remains a key consolidation strategy for patients with relapsed/refractory (R/R) lymphoma. The BEAM regimen (carmustine, etoposide, cytarabine, melphal… |
Clinical Selected reported efficacy | ORR 26% |
Clinical Reported ORR | 26% |
Clinical Result source | ClinicalTrials.gov NCT00233987 |
Clinical Program phase | PHASE_2 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT00233987 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Carmustine |
Overview Company | INSYS Therapeutics Inc |
Overview Modality | ANTIBODY |
Overview Target | Human Immunodeficiency Virus 1 Positive |
Overview Indication | Mantle Cell Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | targeted nanodelivery system, denoted BCNU-FeSeH@EV LF , which integrates magnetic guidance, chemotactic homing, and receptor |
MoA Biomarker | biomarker for hepatocellular carcinoma,lung adenocarcinoma,and papillary renal cell carcinoma |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Rat |
Toxicology Animal (cat.) | Rat |
Toxicology Major finding | Toxicity and efficacy of four carmustine-substituted conditioning regimens followed by autologous stem cell transplantation in lymphoma: a real-world comparative study.. High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) remains a key consolidation strategy for patients with relapsed/refractory (R/R) lymphoma. The BEAM regimen (carmustine, etoposide, cytarabine, melphal… |
Toxicology CRS | Reported |
Clinical Safety signal | Toxicity and efficacy of four carmustine-substituted conditioning regimens followed by autologous stem cell transplantation in lymphoma: a real-world comparative study.. High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) remains a key consolidation strategy for patients with relapsed/refractory (R/R) lymphoma. The BEAM regimen (carmustine, etoposide, cytarabine, melphal… |
Clinical Selected reported efficacy | ORR 26% |
Clinical Reported ORR | 26% |
Clinical Result source | ClinicalTrials.gov NCT00233987 |
Clinical Program phase | PHASE_2 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT00233987 |
추천 비교
추천 비교